GH Research (GHRS) Projected to Announce Earnings on Thursday

GH Research (NASDAQ:GHRS) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.3040) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 26, 2026 at 12:30 PM ET.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, analysts expect GH Research to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

GH Research Stock Up 3.3%

GHRS opened at $29.12 on Wednesday. The firm has a market cap of $2.00 billion, a P/E ratio of -31.65 and a beta of 1.29. GH Research has a 52 week low of $11.32 and a 52 week high of $31.00. The business’s fifty day simple moving average is $25.27 and its 200 day simple moving average is $19.91.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Cantor Fitzgerald lifted their price target on shares of GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Citizens Jmp reduced their target price on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, May 15th. HC Wainwright decreased their price target on shares of GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Citigroup reiterated an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Finally, Zacks Research lowered GH Research from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, GH Research currently has an average rating of “Moderate Buy” and a consensus price target of $40.78.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new position in shares of GH Research in the second quarter valued at $79,000. BNP Paribas Financial Markets increased its stake in GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after buying an additional 10,600 shares during the period. Osaic Holdings Inc. lifted its holdings in GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares in the last quarter. UBS Group AG lifted its holdings in GH Research by 11.5% in the 3rd quarter. UBS Group AG now owns 511,464 shares of the company’s stock worth $7,314,000 after buying an additional 52,882 shares in the last quarter. Finally, Lynx1 Capital Management LP boosted its position in GH Research by 27.5% in the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after buying an additional 1,854,238 shares during the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.